Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey

Atherosclerosis

Volumn 252, Issue , 2016, Pages 161-165

  Schofield, Jonathan ^a,b   Kwok, See ^a,c   France, Michael ^a   Capps, Nigel ^d   Eatough, Ruth ^a   Yadav, Rahul ^b   Ray, Kausik ^e   Soran, Handrean ^a,b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Barlow Medical Centre   (United Kingdom)

^d PRINCESS ROYAL HOSPITAL   (United Kingdom)

^e ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CVD; Education; Familial hypercholesterolaemia; FH; Knowledge; LDL C; Survey

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEALTH CARE PERSONNEL; HEALTH CARE SURVEY; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MALE; MEDICAL EDUCATION; MIDDLE AGED; PATIENT CARE; PREMATURITY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY HEALTH CARE; UNITED KINGDOM; ATTITUDE TO HEALTH; BLOOD; CARDIOLOGY; CARDIOVASCULAR DISEASE; GENERAL PRACTITIONER; HEALTH PROMOTION; MASS SCREENING; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PROCEDURES; QUESTIONNAIRE;

LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOLOGY; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; GENERAL PRACTITIONERS; GUIDELINES AS TOPIC; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PERSONNEL; HEALTH PROMOTION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MASS SCREENING; PHYSICIANS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; UNITED KINGDOM;

EID: 84978852650     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.07.009     Document Type: Article

References (29)

1. [1] Nordestgaard, B.G., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 34 (2013), 3478–3490a.
2. [2] Civeira, F., Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173 (2004), 55–68.
3. [3] Marks, D., et al. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 168 (2003), 1–14.
4. [4] Versmissen, J., et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ, 337, 2008, a2423.
5. [5] Neil, H.A., et al. Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis 179 (2005), 293–297.
6. [6] Pearson, T.A., The prevention of cardiovascular disease: have we really made progress?. Health Aff. (Millwood) 26 (2007), 49–60.
7. [7] Watts, G.F., et al. Familial hypercholesterolemia: a missed opportunity in preventive medicine. Nat. Clin. Pract. Cardiovasc Med. 4 (2007), 404–405.
8. [8] Stock, J., New EAS Consensus Statement on FH: improving the care of FH patients. Atherosclerosis 231 (2013), 69–71.
9. [9] Goldberg, A.C., et al. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the national lipid association expert panel on familial hypercholesterolemia. J. Clin. Lipidol. 5 (2011), S46–S51.
10. [10] Catapano, A.L., Wiklund, O., Think again about cholesterol survey. Atheroscler. Suppl. 20 (2015), 1–5.
11. [11] Familial Hypercholesterolaemia: Identification and Management of Familial Hypercholesterolaemia, 2008, National Institute for Health and Clinical Excellence, London.
12. [12] Neil, H.A., et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ, 321, 2000, 148.
13. [13] Benn, M., et al. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J. Clin. Endocrinol. Metab. 97 (2012), 3956–3964.
14. [14] Familial Hypercholesterolaemia. NICE Quality Standard [QS41], 2013, National Institute for Health and Care Excellence, Manchester.
15. [15] Tomlinson, B., et al. Screening for familial hypercholesterolaemia. Funding is difficult to obtain but screening can be international. BMJ 322 (2001), 1061–1062.
16. [16] Bell, D.A., et al. Opportunistic screening for familial hypercholesterolaemia via a community laboratory. Ann. Clin. Biochem. 49 (2012), 534–537.
17. [17] Bell, D.A., et al. Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia. Heart Lung Circ. 23:4 (2013), 309–313.
18. [18] Hopkins, P.N., et al. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the national lipid association expert panel on familial hypercholesterolemia. J. Clin. Lipidol. 5 (2011), S9–S17.
19. [19] Foody, J.M., Familial hypercholesterolemia: an under-recognized but significant concern in cardiology practice. Clin. Cardiol. 37:2 (2013), 119–125.
20. [20] Dorsch, M.F., et al. Familial hypercholesterolaemia is underdiagnosed after AMI. BMJ, 322, 2001, 111.
21. [21] Williams, R.R., A Genetic Strategy for Preventing Early Deaths - Familial Hypercholesterolemia (FH). 1996, World Health Organization, Human Genetics Programme, Geneva.
22. [22] Gray, J., et al. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart 94 (2008), 754–758.
23. [23] Pang, J., et al. Significant gaps in awareness of familial hypercholesterolemia among physicians in selected Asia-Pacific countries: a pilot study. J. Clin. Lipidol. 9 (2015), 42–48.
24. [24] Brice, P., et al. Familial hypercholesterolaemia: a pressing issue for European health care. Atherosclerosis 231 (2013), 223–226.
25. [25] Horton, J.D., et al. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50:Suppl. (2009), S172–S177.
26. [26] Huijgen, R., et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One, 5, 2010, e9220.
27. [27] Bates, T.R., et al. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin. Pharmacother. 10 (2009), 2973–2985.
28. [28] Marks, D., et al. Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ, 324, 2002, 1303.
29. [29] Vallejo-Vaz, A.J., et al. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 243 (2015), 257–259.